From ImmuPharma website3 Feb 2025 07:48
Https://www.immupharma.co.uk/treatment-cancer-ipp-204106/
The key findings of the study for this compound (referred to in the paper as N6L) were:
Nucleolin inhibition is a new anti-cancer therapeutic strategy that has been shown to dually normalise tumour vasculature and reduce its volume
As a result, it has the potential to improve dramatically the delivery and efficacy of existing chemotherapeutic drugs, and in particular, for difficult-to-treat tumours such as Pancreatic cancer
The publication can be seen by clicking here and the website of Cancer Research is cancerres.aacrjournals.org
In May 2011, IPP-204106 (also referred to as N6L) was chosen to feature on the front cover of ‘Cancer Research’, a prestigious medical journal of the American Association for Cancer Research. The article was entitled ‘A Simple Approach to Cancer Therapy Afforded by Multivalent Pseudopeptides That Target Cell-Surface Nucleoproteins’, and was authored by a number of researchers working at or with the CNRS, the research institution with which ImmuPharma is collaborating.
The key findings of this study are that the compound (referred to in the paper as ‘N6L’):
inhibits growth of several tumour cell lines, xenograft models and blocks angiogenesis
rapidly localizes selectively in tumour tissue
promotes apoptosis (the death of cells, a key approach in the treatment of cancer)
has a novel mechanism of action, acting on nucleophosmin and nucleolin
Click here to download the publication in Cancer Research Publication May 2011 with cover(1)
Click here to download a scientific paper published onNucleolin Plos One(1)
Sign In
Follow the stocks
